A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
Key facts
- Who runs it
- Galmed Research and Development, Ltd.
- Where
- Arlington and Miami, United StatesSee the 2 sites
- Trial code
- Status
- Suspended
- Phase
- Phase 3
- People taking part
- 157 people enrolled
- Started
- 23 Sept 2019
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Aramchol free acid
- Placebo
- Record updated
- 11 February 2026
- Why it stopped
- Interim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Male or female age 18 to 75 years
- Histological confirmation of NASH on a diagnostic liver biopsy by central reading of the slides (biopsy obtained within 6 months prior to randomization or during the screening period)
- Total NAS Score 4 or more with at least 1 in each component of the NAS Score (steatosis ≥1 AND inflammation ≥1 AND ballooning ≥1)
- Fibrosis Stage must be 2 or 3 (Open-Label Part may include up to 30 subjects with fibrosis stage 1)
- Body mass index (BMI) between 25kg/m2 and 40 kg/m2 (Open Label part: BMI <40 kg/m2)
- AST>20 IU/L
- Type 2 diabetes mellitus or prediabetes (Open Label Part only: Type 2 diabetes or prediabetes is not an inclusion criteria)
- For subjects with type 2 diabetes, glycemia must be controlled
- Females of childbearing potential must practice a highly effective method of contraception throughout the study period and for 1 month after treatment discontinuation
- Able to understand the nature of the study and to provide signature of the written informed consent
Who cannot take part
- Prior history or presence of decompensated liver disease
- Known alcohol and/or any other drug abuse or dependence in the last five years
- Weight loss of more than 5% within 3 months prior to screening
- Treatment with drugs that may cause NAFLD within 12 months prior to liver biopsy
- Treatment with some anti-diabetic medications; Unless started prior to biopsy (timeframe depending on drug) and stable
- Current or planned treatment with immunosuppressive drugs
- Model for End-Stage Liver Disease (MELD) score > 12
- Other (acute or chronic) coexisting liver disease based on medical history and/or centralized review of liver histology)
- History of bariatric surgery within 5 years of liver biopsy or planned surgery for weight reduction
- Evidence of any other unstable or untreated clinically significant disease
- Uncontrolled hypertension
- Any other condition that in the opinion of the Investigator warrants exclusion from the study
- ALT or AST >5× upper limit of normal (ULN)
- Platelet count < 150,000mm3
- Alkaline phosphatase ≥2× ULN
- Histologically documented liver cirrhosis (fibrosis stage 4)
- Inability or unwillingness to undergo a liver biopsy
- Abnormal synthetic liver function
- Known or suspected hepatocellular carcinoma (HCC)
Where in United States
- Texas Clinical Research Institute, LLCArlington, United States
- The Public Health Trust of Miami-Dade County, Florida, dba the Jackson Health SystemMiami, United States
About the trial
What the trial wants to find out
An Open-Label Part was added:
Read full original descriptionShow less
This part will enroll in selected sites which are less affected by the COVID-19 pandemic.
150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups according to the post-baseline biopsy.
The objective of the Open-Label Part is:
* To evaluate the safety and PK of twice daily administration (BID) of Aramchol 300mg in subjects with NASH and liver fibrosis. * To explore the kinetics of histological outcome measures and Non-Invasive Tests (NITs) associated with NASH and fibrosis for the treatment duration of 24, 48 and 72 weeks.
All patients will be allocated to Aramchol.
Double Blind Part:
This part is double blind, placebo controlled randomized in subjects with NASH and fibrosis stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes.
The primary objectives of this part of the study are to evaluate the effect of Aramchol as compared to placebo on NASH resolution, fibrosis improvement and clinical outcomes related to progression of liver disease.
Subjects will be randomized to receive Aramchol 300mg BID or matching placebo in a 2:1 randomization ratio.
This double-blind phase of the study will recruit patients once the study will be continued.
The 2 groups in the trial
- Aramchol free acidTreatment being tested
Aramchol 300 mg oral tablet
- PlaceboPlacebo, for comparison
Placebo matching oral tablet
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy PK, Kinetics and Safety of Aramchol in Nonalcoholic Steatohepatitis (NASH) With Open-Label Part
- Publications
- Record updated
- 11 February 2026